85 related articles for article (PubMed ID: 26608919)
1. TCRVγ9 γδ T Cell Response to IL-33: A CD4 T Cell-Dependent Mechanism.
Duault C; Franchini DM; Familliades J; Cayrol C; Roga S; Girard JP; Fournié JJ; Poupot M
J Immunol; 2016 Jan; 196(1):493-502. PubMed ID: 26608919
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid.
Inoue Y; Oda A; Maeda Y; Sumitani R; Oura M; Sogabe K; Maruhashi T; Takahashi M; Fujii S; Nakamura S; Miki H; Hiasa M; Teramachi J; Harada T; Abe M
Int J Hematol; 2024 Jun; 119(6):626-630. PubMed ID: 38581458
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Butyrophilin-Mediated Activation of γδ T Cells from Human Spleen.
Wang C; Lai AY; Baiu DC; Smith KA; Odorico JS; Wilson K; Schreiber T; de Silva S; Gumperz JE
J Immunol; 2024 Jan; 212(2):284-294. PubMed ID: 37991420
[TBL] [Abstract][Full Text] [Related]
4. Antigen-Presenting Human γδ T Cells Promote Intestinal CD4
Tyler CJ; McCarthy NE; Lindsay JO; Stagg AJ; Moser B; Eberl M
J Immunol; 2017 May; 198(9):3417-3425. PubMed ID: 28330898
[TBL] [Abstract][Full Text] [Related]
5. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC
Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215
[TBL] [Abstract][Full Text] [Related]
6. Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens.
Moulin M; Alguacil J; Gu S; Mehtougui A; Adams EJ; Peyrottes S; Champagne E
Cell Mol Life Sci; 2017 Dec; 74(23):4353-4367. PubMed ID: 28669030
[TBL] [Abstract][Full Text] [Related]
7. Vγ9+Vδ2+ T cell control of Listeria monocytogenes growth in infected epithelial cells requires butyrophilin 3A genes.
Fischer K; Bradlerova M; Decker T; Supper V
Sci Rep; 2023 Oct; 13(1):18651. PubMed ID: 37903831
[TBL] [Abstract][Full Text] [Related]
8. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
Cabillic F; Toutirais O; Lavoué V; de La Pintière CT; Daniel P; Rioux-Leclerc N; Turlin B; Mönkkönen H; Mönkkönen J; Boudjema K; Catros V; Bouet-Toussaint F
Cancer Immunol Immunother; 2010 Nov; 59(11):1611-9. PubMed ID: 20582413
[TBL] [Abstract][Full Text] [Related]
9. Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behçet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease.
Triolo G; Accardo-Palumbo A; Dieli F; Ciccia F; Ferrante A; Giardina E; Sano CD; Licata G
Arthritis Res Ther; 2003; 5(5):R262-8. PubMed ID: 12932289
[TBL] [Abstract][Full Text] [Related]
10. γδ T-APCs: a novel tool for immunotherapy?
Moser B; Eberl M
Cell Mol Life Sci; 2011 Jul; 68(14):2443-52. PubMed ID: 21573785
[TBL] [Abstract][Full Text] [Related]
11. Antigen recognition by human γδ T cells: one step closer to knowing.
Eberl M
Immunol Cell Biol; 2020 May; 98(5):351-354. PubMed ID: 32329107
[TBL] [Abstract][Full Text] [Related]
12. Function of γδ T cells in tumor immunology and their application to cancer therapy.
Park JH; Lee HK
Exp Mol Med; 2021 Mar; 53(3):318-327. PubMed ID: 33707742
[TBL] [Abstract][Full Text] [Related]
13. Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy.
Vermijlen D; Ellis P; Langford C; Klein A; Engel R; Willimann K; Jomaa H; Hayday AC; Eberl M
J Immunol; 2007 Apr; 178(7):4304-14. PubMed ID: 17371987
[TBL] [Abstract][Full Text] [Related]
14. γδ T Cells in the Tumor Microenvironment-Interactions With Other Immune Cells.
Chan KF; Duarte JDG; Ostrouska S; Behren A
Front Immunol; 2022; 13():894315. PubMed ID: 35880177
[TBL] [Abstract][Full Text] [Related]
15. Butyrophilin3A proteins and Vγ9Vδ2 T cell activation.
Gu S; Borowska MT; Boughter CT; Adams EJ
Semin Cell Dev Biol; 2018 Dec; 84():65-74. PubMed ID: 29471037
[TBL] [Abstract][Full Text] [Related]
16. How tumors might withstand γδ T-cell attack.
Capietto AH; Martinet L; Fournié JJ
Cell Mol Life Sci; 2011 Jul; 68(14):2433-42. PubMed ID: 21547501
[TBL] [Abstract][Full Text] [Related]
17. Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation.
Lentini NA; Foust BJ; Hsiao CC; Wiemer AJ; Wiemer DF
J Med Chem; 2018 Oct; 61(19):8658-8669. PubMed ID: 30199251
[TBL] [Abstract][Full Text] [Related]
18. γδ T cells, Tregs and epithelial cells interact with IL-33 in the lung.
Darrigues J; Ribot JC
Cell Mol Immunol; 2021 Apr; 18(4):790-791. PubMed ID: 33437049
[No Abstract] [Full Text] [Related]
19. Differential Responsiveness of Innate-like IL-17- and IFN-γ-Producing γδ T Cells to Homeostatic Cytokines.
Corpuz TM; Stolp J; Kim HO; Pinget GV; Gray DH; Cho JH; Sprent J; Webster KE
J Immunol; 2016 Jan; 196(2):645-54. PubMed ID: 26673141
[TBL] [Abstract][Full Text] [Related]
20. Chronic Inflammation and γδ T Cells.
Fay NS; Larson EC; Jameson JM
Front Immunol; 2016; 7():210. PubMed ID: 27303404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
